KR102434557B1 - Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스 - Google Patents

Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스 Download PDF

Info

Publication number
KR102434557B1
KR102434557B1 KR1020217030387A KR20217030387A KR102434557B1 KR 102434557 B1 KR102434557 B1 KR 102434557B1 KR 1020217030387 A KR1020217030387 A KR 1020217030387A KR 20217030387 A KR20217030387 A KR 20217030387A KR 102434557 B1 KR102434557 B1 KR 102434557B1
Authority
KR
South Korea
Prior art keywords
human
mouse
domain
segment
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217030387A
Other languages
English (en)
Korean (ko)
Other versions
KR20210118972A (ko
Inventor
린 맥도날드
션 스티븐스
자간 구레르
캐롤리나 에이. 호시아와
앤드류 제이. 머피
Original Assignee
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44543797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102434557(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리제너론 파아마슈티컬스, 인크. filed Critical 리제너론 파아마슈티컬스, 인크.
Publication of KR20210118972A publication Critical patent/KR20210118972A/ko
Application granted granted Critical
Publication of KR102434557B1 publication Critical patent/KR102434557B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217030387A 2010-08-02 2011-08-02 Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스 Active KR102434557B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36990910P 2010-08-02 2010-08-02
US61/369,909 2010-08-02
KR1020207027965A KR102306967B1 (ko) 2010-08-02 2011-08-02 Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스
PCT/US2011/046196 WO2012018764A1 (en) 2010-08-02 2011-08-02 Mice that make binding proteins comprising vl domains

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207027965A Division KR102306967B1 (ko) 2010-08-02 2011-08-02 Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스

Publications (2)

Publication Number Publication Date
KR20210118972A KR20210118972A (ko) 2021-10-01
KR102434557B1 true KR102434557B1 (ko) 2022-08-23

Family

ID=44543797

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020217030387A Active KR102434557B1 (ko) 2010-08-02 2011-08-02 Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스
KR1020207027965A Active KR102306967B1 (ko) 2010-08-02 2011-08-02 Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스
KR1020137004960A Active KR102008655B1 (ko) 2010-08-02 2011-08-02 Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스
KR1020197022706A Active KR102163138B1 (ko) 2010-08-02 2011-08-02 Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020207027965A Active KR102306967B1 (ko) 2010-08-02 2011-08-02 Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스
KR1020137004960A Active KR102008655B1 (ko) 2010-08-02 2011-08-02 Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스
KR1020197022706A Active KR102163138B1 (ko) 2010-08-02 2011-08-02 Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스

Country Status (27)

Country Link
US (7) US9516868B2 (enExample)
EP (3) EP2601298B1 (enExample)
JP (6) JP6146913B2 (enExample)
KR (4) KR102434557B1 (enExample)
CN (4) CN103154255B (enExample)
AU (1) AU2011285919C1 (enExample)
BR (1) BR112013002695B1 (enExample)
CA (2) CA2807282A1 (enExample)
CY (1) CY1118562T1 (enExample)
DK (1) DK2601298T3 (enExample)
ES (1) ES2612459T3 (enExample)
HK (1) HK1217511A1 (enExample)
HR (1) HRP20170322T1 (enExample)
HU (1) HUE031903T2 (enExample)
IL (4) IL315833A (enExample)
LT (1) LT2601298T (enExample)
MX (5) MX2018014787A (enExample)
MY (1) MY172618A (enExample)
NZ (2) NZ606824A (enExample)
PL (1) PL2601298T3 (enExample)
PT (1) PT2601298T (enExample)
RS (1) RS55495B1 (enExample)
RU (2) RU2750219C2 (enExample)
SG (3) SG187673A1 (enExample)
SI (1) SI2601298T1 (enExample)
SM (2) SMT201700023T1 (enExample)
WO (1) WO2012018764A1 (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110020860A (ko) * 2008-05-23 2011-03-03 알리바 바이오파마수티컬스, 아이엔씨. 유전자 삽입동물에서 단일 ｖｌ 도메인 항체를 생산하는 방법
EP2564695B1 (en) 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
ES2603559T5 (es) 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
CA2807282A1 (en) 2010-08-02 2012-02-09 Regeneron Pharamaceuticals, Inc. Mice that make binding proteins comprising vl domains
FI3865581T3 (fi) 2011-08-05 2024-11-02 Regeneron Pharma Humanisoituja universaaleja kevytketjun hiiriä
EP2758534B1 (en) 2011-09-19 2020-04-29 Kymab Limited Animals, repertoires & methods for the production of human antibodies
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR102762747B1 (ko) 2011-10-17 2025-02-05 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 마우스
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US9706759B2 (en) 2011-12-20 2017-07-18 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
EP3912465A1 (en) * 2012-02-01 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
WO2013134880A1 (en) * 2012-03-14 2013-09-19 Innovative Targeting Solutions Inc. Generating targeted sequence diversity in proteins
WO2013134881A1 (en) 2012-03-14 2013-09-19 Innovative Targeting Solutions Inc. Generating targeted sequence diversity in fusion proteins
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
KR102266274B1 (ko) 2012-06-12 2021-06-17 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
TR201810255T4 (tr) * 2013-02-20 2018-08-27 Regeneron Pharma Modifiye edilmiş immunoglobulin ağır zincir sekanslarına sahip olan insan olmayan hayvanlar.
LT3501272T (lt) * 2013-03-13 2023-03-27 Regeneron Pharmaceuticals, Inc. Pelės, vykdančios imunoglobulino lengvosios grandinės riboto rinkinio raišką
CA2902872A1 (en) 2013-03-15 2014-09-18 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
MX373528B (es) 2013-08-26 2020-04-21 Regeneron Pharma Composiciones farmacéuticas que contienen diasterómeros macrólidos, métodos para su síntesis y usos terapéuticos.
FR3011249A1 (enExample) * 2013-10-01 2015-04-03 Kymab Ltd
AU2014330922A1 (en) 2013-10-01 2016-03-03 Kymab Limited Animal models and therapeutic molecules
CA3124228C (en) * 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
SG11201607015VA (en) * 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
WO2016149678A1 (en) * 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
BR112017020149A8 (pt) 2015-03-27 2023-05-02 Regeneron Pharma Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
EP4465050A3 (en) 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau antibodies and methods of use
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
EA039072B9 (ru) 2016-01-25 2022-02-04 Регенерон Фармасьютикалз, Инк. Производные майтанзиноида, их конъюгаты и способы применения
EP3411476B1 (en) 2016-02-04 2024-04-24 Trianni, Inc. Enhanced production of immunoglobulins
EP4368637A3 (en) 2016-05-20 2024-07-10 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
KR102784608B1 (ko) 2016-06-03 2025-03-27 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
MX394528B (es) 2016-11-08 2025-03-24 Regeneron Pharma Esteroides y conjugados de proteinas de los mismos.
CN110248959B (zh) 2016-12-07 2023-06-30 基因泰克公司 抗tau抗体和使用方法
EP3551220B1 (en) 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
KR102777514B1 (ko) * 2017-01-19 2025-03-06 옴니에이비 오퍼레이션스, 인코포레이티드 다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체
KR20250008984A (ko) 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
EP3679070A1 (en) 2017-09-07 2020-07-15 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
SG11202004151YA (en) 2017-11-07 2020-06-29 Regeneron Pharma Hydrophilic linkers for antibody drug conjugates
CA3086926A1 (en) 2018-01-08 2019-07-11 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof
SMT202500038T1 (it) 2018-03-24 2025-03-12 Regeneron Pharma Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
IL314733A (en) 2018-03-26 2024-10-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
SG11202010909RA (en) 2018-05-09 2020-12-30 Regeneron Pharma Anti-msr1 antibodies and methods of use thereof
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
JP2020146302A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146301A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146310A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146309A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146314A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146316A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146304A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146318A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146299A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146313A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146315A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146297A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146305A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146303A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146300A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146317A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146307A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146306A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146312A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146308A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146298A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
CA3179154A1 (en) 2020-04-16 2021-10-21 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
BR112023000489A2 (pt) 2020-07-13 2023-03-28 Regeneron Pharma Análogos de camptotecina conjugados a um resíduo de glutamina em uma proteína, e seu uso
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
AU2021339892A1 (en) 2020-09-14 2023-04-27 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
CA3199879A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
JP2025502147A (ja) 2022-01-12 2025-01-24 リジェネロン ファーマシューティカルズ，インク． タンパク質中のグルタミン残基にコンジュゲートしたカンプトテシンアナログおよびその使用
AU2023212994A1 (en) 2022-01-28 2024-08-08 Georgiamune Inc. Antibodies to programmed cell death protein 1 that are pd-1 agonists
AU2023407365A1 (en) 2022-12-21 2025-07-31 Regeneron Pharmaceuticals, Inc. Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
WO2025096921A1 (en) 2023-11-03 2025-05-08 Regeneron Pharmaceuticals, Inc. Peptide acids as a glp1r agonist and antibody-drug conjugates thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20060015957A1 (en) 1991-08-28 2006-01-19 Genpharm International, Inc. Transgenic non-human animals for producing chimeric antibodies
WO2009143472A2 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
WO2009157771A2 (en) 2008-06-27 2009-12-30 Merus B.V. Antibody producing non-human mammals
US20100310586A1 (en) 2007-07-27 2010-12-09 ARETA INTERNATIONAL S.r.l Idiotypic vaccine
WO2011004192A1 (en) 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977081A (en) 1987-05-04 1990-12-11 Adi Diagnostics, Inc. Stable rabbit-mouse hybridomas and secretion products thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5075181A (en) 1989-05-05 1991-12-24 Kennametal Inc. High hardness/high compressive stress multilayer coated tool
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU8212291A (en) 1990-07-10 1992-02-04 Nkk Corporation Hybridoma which produces avian specific immunoglobulin g
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2835787B2 (ja) 1991-03-22 1998-12-14 キヤノン株式会社 強誘電性液晶素子
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5150584A (en) 1991-09-26 1992-09-29 General Motors Corporation Method and apparatus for detecting low refrigerant charge
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
PL309249A1 (en) 1992-12-01 1995-10-02 Protein Design Labs Humanised antibodies against l-selectin
DE4309308C1 (de) 1993-03-23 1994-04-14 Siemens Nixdorf Inf Syst Belüftungssystem für Schränke mit stark wärmeerzeugenden elektronischen Funktionseinheiten
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
AU7326796A (en) 1995-10-30 1997-05-22 Spectral Diagnostics Inc. Stable chicken b-cell line and method of use thereof
AU3507297A (en) 1996-06-26 1998-01-14 Baylor College Of Medicine Chromosomal rearrangement by insertion of two recombination substrates
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
CN1203922A (zh) 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
CA2373638A1 (en) 1999-05-27 2000-12-07 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
CA2422155A1 (en) * 2000-08-03 2002-02-14 Wim Van Schooten Production of humanized antibodies in transgenic animals
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
WO2002092812A1 (fr) 2001-05-11 2002-11-21 Kirin Beer Kabushiki Kaisha CHROMOSOME HUMAIN ARTIFICIEL CONTENANT LE GENE A CHAINE LEGERE DE L'ANTICORPS HUMAIN $g(l)
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
FR2827302B1 (fr) * 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
EP3269235B1 (en) * 2001-11-30 2022-01-26 Amgen Fremont Inc. Transgenic mice bearing human ig lambda light chain genes
JP2005512044A (ja) 2001-12-03 2005-04-28 アブジェニックス・インコーポレーテッド 結合特性に基づく抗体分類
US20030182675A1 (en) 2002-03-22 2003-09-25 Origen Therapeutics Functional disruption of avian immunoglobulin genes
WO2003081993A2 (en) 2002-03-22 2003-10-09 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
FI117110B (fi) 2002-07-05 2006-06-15 Outokumpu Oy Anodin syöttö sulatusreaktoriin
CN105884893A (zh) 2002-07-18 2016-08-24 莫鲁斯有限公司 抗体混合物的重组生产
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
GB0228210D0 (en) * 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
WO2004106375A1 (en) * 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005001087A2 (en) 2003-06-11 2005-01-06 Regeneron Pharmaceuticals, Inc. Methods of modifying genes in eukaryotic cells
CN1852925A (zh) 2003-07-15 2006-10-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
US20050153392A1 (en) 2003-08-11 2005-07-14 Roland Buelow Transgenesis with humanized immunoglobulin loci
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
WO2005038001A2 (en) 2003-10-14 2005-04-28 Therapeutic Human Polyclonals, Inc. Improved transgenesis by sperm-mediated gene transfer
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
WO2005079696A1 (de) 2004-02-20 2005-09-01 Woodwelding Ag In knochengewebe zu implantierendes implantat und verfahren zu dessen herstellung und implantation
LT2311874T (lt) * 2004-07-22 2017-11-27 Erasmus University Medical Center Rotterdam Rišančiosios molekulės
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
US20080184380A1 (en) 2004-10-22 2008-07-31 Therapeutic Human Polyclonals Inc. Suppression of Endogenous Immunoglobulin Expression in Non-Human Transgenic Animals
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
US20090307787A1 (en) 2006-01-25 2009-12-10 Franklin Gerardus Grosveld Generation of heavy-chain only antibodies in transgenic animals
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
WO2008027986A2 (en) 2006-09-01 2008-03-06 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
PL2069403T3 (pl) * 2006-10-02 2015-08-31 Regeneron Pharma Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2336329B8 (en) 2007-06-01 2012-11-21 Omt, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenis human idiotype antibodies
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
EP2626371A1 (en) * 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
US9693539B2 (en) 2007-08-10 2017-07-04 E. R. Squibb & Sons, L.L.C. HCO32 and HCO27 and related examples
CN101970491A (zh) 2007-08-30 2011-02-09 沃尔特及伊莱萨霍尔医学研究院 树突状细胞标记物及其用途
RU2526512C2 (ru) 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Модифицированная константная область антитела
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CA2721231C (en) 2008-04-14 2015-10-06 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
LT2346994T (lt) 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
AU2009329365B2 (en) 2008-12-18 2016-01-14 Roger Kingdon Craig Non-human transgenic animals expressing humanised antibodies and use thereof
CA2750520C (en) 2009-02-04 2017-12-05 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
SG175078A1 (en) * 2009-04-07 2011-11-28 Roche Glycart Ag Bispecific anti-erbb-1/anti-c-met antibodies
ES2865648T3 (es) 2009-06-26 2021-10-15 Regeneron Pharma Anticuerpos biespecíficos fácilmente aislados con formato de inmunoglobulina nativa
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
CN101620635A (zh) * 2009-08-07 2010-01-06 中兴通讯股份有限公司 页面数据获取方法及服务器、页面更新方法及服务器
SMT201900251T1 (it) 2009-12-10 2019-07-11 Regeneron Pharma Topi che producono anticorpi della catena pesante
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
ES2603559T5 (es) 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
CA2802591A1 (en) 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
CN104404050B (zh) * 2010-06-22 2018-06-08 瑞泽恩制药公司 杂交轻链小鼠
CA2807282A1 (en) * 2010-08-02 2012-02-09 Regeneron Pharamaceuticals, Inc. Mice that make binding proteins comprising vl domains
EP2638155A1 (en) 2010-11-08 2013-09-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
HUE047687T2 (hu) 2011-02-25 2020-05-28 Regeneron Pharma ADAM6 egér
BR112013020338A2 (pt) 2011-02-28 2016-10-18 Hoffmann La Roche proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
US20120310284A1 (en) 2011-06-03 2012-12-06 Royal Oak Industries Polyaxial pedicle screw
FI3865581T3 (fi) 2011-08-05 2024-11-02 Regeneron Pharma Humanisoituja universaaleja kevytketjun hiiriä
EP2758534B1 (en) 2011-09-19 2020-04-29 Kymab Limited Animals, repertoires & methods for the production of human antibodies
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR102762747B1 (ko) 2011-10-17 2025-02-05 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 마우스
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9706759B2 (en) 2011-12-20 2017-07-18 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
EP3912465A1 (en) 2012-02-01 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
MX369747B (es) 2013-04-16 2019-11-20 Regeneron Pharma Modificación dirigida del genoma de rata.
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
WO2016149678A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060015957A1 (en) 1991-08-28 2006-01-19 Genpharm International, Inc. Transgenic non-human animals for producing chimeric antibodies
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2004524841A (ja) * 2001-02-16 2004-08-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 真核生物細胞を改変する方法
US20100310586A1 (en) 2007-07-27 2010-12-09 ARETA INTERNATIONAL S.r.l Idiotypic vaccine
WO2009143472A2 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
WO2009157771A2 (en) 2008-06-27 2009-12-30 Merus B.V. Antibody producing non-human mammals
WO2011004192A1 (en) 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Generation of heavy-chain-only antibodies in mice"PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES(PNAS), vol.103, no. 41, pages 15130-15135(2006.10.10.)

Also Published As

Publication number Publication date
HRP20170322T1 (hr) 2017-04-21
CY1118562T1 (el) 2017-07-12
US20210163628A1 (en) 2021-06-03
MX350591B (es) 2017-09-11
KR20210118972A (ko) 2021-10-01
KR102008655B1 (ko) 2019-08-08
MX2013001360A (es) 2013-06-28
EP2601298B1 (en) 2016-11-30
HK1181810A1 (en) 2013-11-15
WO2012018764A1 (en) 2012-02-09
NZ707327A (en) 2017-01-27
SG187673A1 (en) 2013-03-28
JP2020078328A (ja) 2020-05-28
KR102163138B1 (ko) 2020-10-08
KR102306967B1 (ko) 2021-10-01
SMT201700023B (it) 2017-03-08
RU2013109068A (ru) 2014-09-10
AU2011285919C1 (en) 2015-09-17
PL2601298T3 (pl) 2017-03-31
US20170226231A1 (en) 2017-08-10
EP2947151A1 (en) 2015-11-25
JP2016054746A (ja) 2016-04-21
PT2601298T (pt) 2017-01-09
US20140130194A1 (en) 2014-05-08
EP2601298A1 (en) 2013-06-12
US20170223939A1 (en) 2017-08-10
ES2612459T3 (es) 2017-05-17
JP2018046872A (ja) 2018-03-29
IL271804B2 (en) 2025-03-01
CA3250882A1 (en) 2025-11-29
DK2601298T3 (en) 2017-02-27
US9516868B2 (en) 2016-12-13
SG10201912639SA (en) 2020-02-27
NZ724003A (en) 2021-03-26
US9686970B2 (en) 2017-06-27
IL224523B (en) 2018-04-30
NZ740900A (en) 2023-11-24
CN113150121A (zh) 2021-07-23
US10954310B2 (en) 2021-03-23
CN113150121B (zh) 2024-08-16
BR112013002695A2 (pt) 2017-03-01
CN118791596A (zh) 2024-10-18
SG10201504971QA (en) 2015-07-30
US20120096572A1 (en) 2012-04-19
CA2807282A1 (en) 2012-02-09
IL271804A (en) 2020-02-27
JP6146913B2 (ja) 2017-06-14
RU2017106292A3 (enExample) 2020-12-10
JP2019047805A (ja) 2019-03-28
LT2601298T (lt) 2017-03-10
RU2017106292A (ru) 2019-01-21
IL271804B1 (en) 2024-11-01
MX363084B (es) 2019-03-07
CN113150121B9 (zh) 2024-11-26
JP7078400B2 (ja) 2022-05-31
CN105753979A (zh) 2016-07-13
MX345251B (es) 2017-01-23
RU2750219C2 (ru) 2021-06-24
MX2018014787A (es) 2023-02-14
KR20130100277A (ko) 2013-09-10
SMT201700023T1 (it) 2017-03-08
IL258338B (en) 2020-01-30
CN103154255A (zh) 2013-06-12
MY172618A (en) 2019-12-06
NZ606824A (en) 2015-05-29
HUE031903T2 (en) 2017-08-28
KR20200116547A (ko) 2020-10-12
BR112013002695B1 (pt) 2023-01-24
JP6759303B2 (ja) 2020-09-23
SI2601298T1 (sl) 2017-03-31
JP2021119792A (ja) 2021-08-19
MX2023001793A (es) 2023-03-10
US20220177606A1 (en) 2022-06-09
JP7110257B2 (ja) 2022-08-01
IL315833A (en) 2024-11-01
CN105753979B (zh) 2021-05-07
KR20190095511A (ko) 2019-08-14
US12486335B2 (en) 2025-12-02
EP3960865A1 (en) 2022-03-02
IL258338A (en) 2018-05-31
RU2612903C2 (ru) 2017-03-13
RS55495B1 (sr) 2017-04-28
HK1217511A1 (en) 2017-01-13
US20140130193A1 (en) 2014-05-08
AU2011285919A1 (en) 2013-02-28
CN103154255B (zh) 2016-04-06
JP2013535213A (ja) 2013-09-12
AU2011285919B2 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
US12486335B2 (en) Mice that make VL binding proteins
AU2017219079C1 (en) Mice that make binding proteins comprising vl domains
RU2847568C2 (ru) Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
HK40069751A (en) Mice that make binding proteins comprising vl domains
HK1181810B (en) Mice that make binding proteins comprising vl domains

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4